The artificial element technetium, in the form of its short-lived gamma ray emitting radionuclide 99mTc, plays a very important role in routine nuclear medicine imaging. More than 85% of all procedures in the USA involve the administration of a 99mTc-labeled radiopharmaceutical. This renewal application describes a continuing program of research that combined basic chemical studies of the element together with applications of that chemistry towards the design of new imaging agents. In addition a parallel program will explore the chemistry of the closely related metallic element rhenium and its applications in radiotherapy. The basic studies of technetium will include the use of new synthetic intermediates discovered in the current cycle to explore the rapidly developing low-oxidation-state chemistry, the use of nitrogen donor ligands to form new complexes in low and high oxidation states, and an investigation of its organometallic chemistry. New strategies will be investigated for conjugation of technetium to biologically active molecules using several different classes of complexes that leave free coordinating sites for the attachment of biological ligands. The first application of the chemistry will involve an investigation of a variety of cationic technetium complexes as myocardial imaging agents that are sensitive to the metabolic state of the tissue. Such agents would be important in the evaluation of salvageable tissue following an ischemic event. The second area will explore several avenues towards tumor detection, including relatively simple cationic complexes and 99mTc-labeled natural killer (NK) cells. In the applications of rhenium chemistry, reliable methods for synthesizing required compounds at tracer concentrations will be devised. This will essentially parallel earlier developments in technetium chemistry. This chemistry will then be applied to a search for soluble agents suitable for radiation synovectomy, particularly for treatment of rheumatoid arthritis and pigmented villonodular synovitis. The use of soluble agents may allow a wider use of this therapy in joints smaller than the knee and ankle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA034970-15
Application #
3482296
Study Section
Diagnostic Radiology Study Section (RNM)
Project Start
1977-02-01
Project End
1996-12-31
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
15
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Cheng, Zhen; Mahmood, Ashfaq; Li, Huazhi et al. (2005) [99mTcOAADT]-(CH2)2-NEt2: a potential small-molecule single-photon emission computed tomography probe for imaging metastatic melanoma. Cancer Res 65:4979-86
Friebe, M; Mahmood, A; Spies, H et al. (2000) '3+1' mixed-ligand oxotechnetium(V) complexes with affinity for melanoma: synthesis and evaluation in vitro and in vivo. J Med Chem 43:2745-52
Barbarics, E; Kronauge, J F; Davison, A et al. (1998) Uptake of cationic technetium complexes in cultured human carcinoma cells and human xenografts. Nucl Med Biol 25:667-73
Barbarics, E; Kronauge, J F; Cohen, D et al. (1998) Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 58:276-82
Packard, A B; Barbarics, E; Kronauge, J F et al. (1997) Comparison of uptake of 99mTc-alkylisonitriles in the rat 9L gliosarcoma tumor model. Nucl Med Biol 24:21-5
Delmon-Moingeon, L I; Mahmood, A; Davison, A et al. (1996) A new approach to labeling cells with technetium-99m, Part II. Evaluation of radiolabeled human-lymphocyte immune functions. Nucl Med Biol 23:87-95
Mahmood, A; Delmon-Moingeon, L I; Limpa-Amara, N et al. (1996) A new approach to labeling cells with technetium-99m, Part I. Preparation of modified polylysine and in vitro cell labeling. Nucl Med Biol 23:79-85
Herman, L W; Sharma, V; Kronauge, J F et al. (1995) Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J Med Chem 38:2955-63
Verdera, S; Lopez, J J; Tagle, R et al. (1994) Radiopharmacological evaluation in dogs of a new renal function agent. J Nucl Biol Med 38:79-85
Piwnica-Worms, D P; Kronauge, J F; LeFurgey, A et al. (1994) Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magn Reson Imaging 12:641-52

Showing the most recent 10 out of 15 publications